PL2003120T3 - Pochodne azapeptydu jako inhibitory proteazy HIV - Google Patents

Pochodne azapeptydu jako inhibitory proteazy HIV

Info

Publication number
PL2003120T3
PL2003120T3 PL08252023T PL08252023T PL2003120T3 PL 2003120 T3 PL2003120 T3 PL 2003120T3 PL 08252023 T PL08252023 T PL 08252023T PL 08252023 T PL08252023 T PL 08252023T PL 2003120 T3 PL2003120 T3 PL 2003120T3
Authority
PL
Poland
Prior art keywords
protease inhibitors
hiv protease
azapeptide derivatives
azapeptide
derivatives
Prior art date
Application number
PL08252023T
Other languages
English (en)
Polish (pl)
Inventor
Scott L Harbeson
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of PL2003120T3 publication Critical patent/PL2003120T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
PL08252023T 2007-06-12 2008-06-12 Pochodne azapeptydu jako inhibitory proteazy HIV PL2003120T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
EP08252023A EP2003120B9 (en) 2007-06-12 2008-06-12 Azapeptide derivatives as HIV protease inhibitors

Publications (1)

Publication Number Publication Date
PL2003120T3 true PL2003120T3 (pl) 2010-04-30

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08252023T PL2003120T3 (pl) 2007-06-12 2008-06-12 Pochodne azapeptydu jako inhibitory proteazy HIV

Country Status (25)

Country Link
US (4) US20090036357A1 (OSRAM)
EP (3) EP2322509B1 (OSRAM)
JP (1) JP2010529196A (OSRAM)
KR (2) KR101185899B1 (OSRAM)
CN (2) CN101711237B (OSRAM)
AR (1) AR066972A1 (OSRAM)
AT (2) ATE447554T1 (OSRAM)
AU (1) AU2008267048C1 (OSRAM)
BR (2) BRPI0823520A2 (OSRAM)
CA (1) CA2692028C (OSRAM)
CO (1) CO6241121A2 (OSRAM)
CY (1) CY1109766T1 (OSRAM)
DE (1) DE602008000255D1 (OSRAM)
DK (1) DK2003120T3 (OSRAM)
ES (3) ES2356334T3 (OSRAM)
HR (1) HRP20100065T1 (OSRAM)
MX (1) MX2009013565A (OSRAM)
PL (1) PL2003120T3 (OSRAM)
PT (1) PT2003120E (OSRAM)
RS (1) RS51226B (OSRAM)
RU (2) RU2448958C2 (OSRAM)
SI (1) SI2003120T1 (OSRAM)
TW (1) TW200908970A (OSRAM)
WO (1) WO2008156632A1 (OSRAM)
ZA (1) ZA200909079B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
RU2448958C2 (ru) * 2007-06-12 2012-04-27 Консерт Фармасьютикалз, Инк. Производные азапептидов
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
LT2720989T (lt) 2011-06-20 2016-11-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
RS62466B1 (sr) * 2015-12-02 2021-11-30 Merck Sharp & Dohme Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
SMT202200011T1 (it) 2017-09-27 2022-03-21 Incyte Corp Sali di derivati di pirrolotriazina utili come inibitori di tam
KR102839002B1 (ko) 2018-06-29 2025-07-29 인사이트 코포레이션 Axl/mer 억제제의 제형
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591125B2 (en) 1985-05-15 1989-11-30 Wellcome Foundation Limited, The Therapeutic nucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CA2605872A1 (en) 1992-12-29 1994-06-30 Abbott Laboratories Intermediates for retroviral protease inhibiting compounds
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
RU2316341C2 (ru) 2001-08-31 2008-02-10 Бристол-Маерс Сквибб Компани Применение атазанавира в терапии вич-инфекции
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2676567A1 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
MXPA06015108A (es) * 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20070259894A1 (en) 2004-12-03 2007-11-08 Kelem Kassahun Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
MX2009002398A (es) 2006-09-05 2009-03-16 Schering Corp Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
RU2448958C2 (ru) 2007-06-12 2012-04-27 Консерт Фармасьютикалз, Инк. Производные азапептидов
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
EP2003120B1 (en) 2009-11-04
KR101185899B1 (ko) 2012-09-27
ATE536343T1 (de) 2011-12-15
RU2448958C2 (ru) 2012-04-27
ES2394952T3 (es) 2013-02-07
AU2008267048C1 (en) 2013-01-17
AR066972A1 (es) 2009-09-23
ATE447554T1 (de) 2009-11-15
DE602008000255D1 (de) 2009-12-17
US20110009355A1 (en) 2011-01-13
RU2012101881A (ru) 2013-07-27
EP2003120B9 (en) 2010-06-02
EP2003120A1 (en) 2008-12-17
RS51226B (sr) 2010-12-31
US8258309B2 (en) 2012-09-04
EP2322509B1 (en) 2012-08-22
ES2356334T3 (es) 2011-04-07
US20090036357A1 (en) 2009-02-05
RU2010100821A (ru) 2011-07-20
JP2010529196A (ja) 2010-08-26
EP2116532A1 (en) 2009-11-11
AU2008267048A1 (en) 2008-12-24
WO2008156632A1 (en) 2008-12-24
HK1127345A1 (en) 2009-09-25
ZA200909079B (en) 2011-05-25
HK1136576A1 (en) 2010-07-02
US8158805B2 (en) 2012-04-17
US20130041156A1 (en) 2013-02-14
AU2008267048B2 (en) 2012-05-31
SI2003120T1 (sl) 2010-03-31
EP2322509A1 (en) 2011-05-18
ES2395137T3 (es) 2013-02-08
CN101711237A (zh) 2010-05-19
BRPI0823520A2 (pt) 2013-12-17
CO6241121A2 (es) 2011-01-20
BRPI0813911A2 (pt) 2012-02-22
KR20100020033A (ko) 2010-02-19
HRP20100065T1 (hr) 2010-03-31
US20120165288A1 (en) 2012-06-28
KR20120029480A (ko) 2012-03-26
MX2009013565A (es) 2010-06-02
CY1109766T1 (el) 2014-09-10
TW200908970A (en) 2009-03-01
CA2692028C (en) 2013-06-04
CN102424668A (zh) 2012-04-25
CN101711237B (zh) 2013-08-07
PT2003120E (pt) 2010-02-11
DK2003120T3 (da) 2010-03-15
CA2692028A1 (en) 2008-12-24
EP2116532B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
PT2003120E (pt) Derivados de azapéptido como inibidores de protease de hiv
IL197777A0 (en) Enantiomerically pure phosphoindoles as hiv inhibitors
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
EP2632895A4 (en) HIV PROTEASE INHIBITORS
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL183850A0 (en) Hiv protease inhibitors
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
EP2313426A4 (en) NEW PROTEASE INHIBITORS
ZA200804607B (en) Substituted aminophenylsulfonamide compounds as HIV protease inhibitor
EP2134336A4 (en) HIV PROTEASE INHIBITORS DERIVED FROM BENZOFURAN
ZA201102179B (en) Protease inhibitors
EP1855672A4 (en) HIV PROTEASE INHIBITORS
ZA200902172B (en) Enantiomerically pure phosphoindoles as HIV inhibitors
ZA200706305B (en) HIV protease inhibitors
GB0817425D0 (en) Protease inhibitors
ZA200804610B (en) Aminophenylsulfonamide derivatives as HIV protease inhibitor
HK1147995A (en) Sulfonamides as zap-70 inhibitors
GB0712544D0 (en) Protease inhibitors
GB0705213D0 (en) Protease inhibitors
GB0705212D0 (en) Protease inhibitors
GB0700378D0 (en) Protease inhibitors
GB0700369D0 (en) Protease inhibitors
GB0712176D0 (en) Protease inhibitors
GB0712543D0 (en) Protease inhibitors
HK1154384A (en) Protease inhibitors